| Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. | |
| | |
MedLine Citation:
|
PMID: 17531571 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The purpose of this study was to define binodenoson dosing regimens that produce coronary hyperemia comparable to those of adenosine and that are tolerated well by patients. An open-label, randomized, parallel-group, multicenter study enrolled adult patients who had completed diagnostic cardiac catheterization. Coronary blood flow velocity (CBFV) was measured with a Doppler flow wire, and CBFV reserve was determined before binodenoson administration. Patients (n = 133) received a 3-minute infusion of 0.3, 0.5, or 1 microg/kg/min or a bolus intravenous injection of 1.5 or 3 microg/kg. Coronary hyperemic responses were evident within seconds of administering binodenoson, and the magnitudes and durations of coronary hyperemic responses were dose related. The 1.5- and 3-microg/kg doses, by infusion or bolus, produced maximal coronary hyperemia equivalent to CBFV reserve. All doses transiently decrease blood pressure and increased heart rate and rate-pressure product. In conclusion, the 1.5-microg/kg binodenoson bolus dose produced nearly maximal coronary hyperemia by 4.5 +/- 3.7 minutes that was sustained for 7.4 +/- 6.86 minutes, was accompanied by modest changes in blood pressure, heart rate, and rate-pressure product, and produced no adverse changes on electrocardiogram, including no second- or third-degree atrioventricular block. |
| | |
Authors:
|
John McB Hodgson; Nabil Dib; Morton J Kern; Richard G Bach; Richard J Barrett |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial Date: 2007-04-16 |
Journal Detail:
|
Title: The American journal of cardiology Volume: 99 ISSN: 0002-9149 ISO Abbreviation: Am. J. Cardiol. Publication Date: 2007 Jun |
Date Detail:
|
Created Date: 2007-05-28 Completed Date: 2007-08-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 1507-12 Citation Subset: AIM; IM |
Affiliation:
|
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. john.hodgson@chw.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenosine
/
administration & dosage,
analogs & derivatives*,
pharmacology Adult Aged Aged, 80 and over Analysis of Variance Blood Flow Velocity / drug effects Blood Pressure / drug effects Coronary Circulation / drug effects* Coronary Vessels / drug effects, physiopathology, ultrasonography Dose-Response Relationship, Drug Female Heart Rate / drug effects Humans Hyperemia / chemically induced, physiopathology Infusions, Intravenous Injections, Intravenous Male Middle Aged Receptor, Adenosine A2A / agonists* Time Factors Treatment Outcome Ultrasonography, Doppler Vascular Resistance / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Receptor, Adenosine A2A; 144348-08-3/2-(cyclohexylmethylidenehydrazino)adenosine; 58-61-7/Adenosine |
| Comments/Corrections | |
Comment In:
|
Am J Cardiol. 2007 Jun 1;99(11):1619-20
[PMID:
17531594
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparison of values of wide-range C-reactive protein to high-sensitivity C-reactive protein in pati...
Next Document: Effect of anemia on hemorrhagic complications and mortality following percutaneous coronary interven...